Benefiting from the successful development of KRASG12C inhibitors, the current therapeutic strategy for NSCLC with G12C mutation is to combine KRASG12C inhibitors with other related pathway inhibitors, targeting immune checkpoints, EGFR, SHP2, SOS1, MEK, PI3K, mTOR, CDK4/6 or others, to improve the therapeutic effect.264, 265, 266, 267, 268, 269. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.